22479-95-4

Basic information

• Product Name: DIMETHYL 4-HYDROXYPHTHALATE
• Synonyms: 4-HYDROXYPHTHALIC ACID DIMETHYL ESTER;DIMETHYL 4-HYDROXYPHTHALATE;Einecs 245-023-9;1,2-diMethyl 4-hydroxybenzene-1,2-dicarboxylate;Dimethyl 4-hydroxy-1,2-benzenedicarboxylate;4-hydroxybenzene-1,2-dicarboxylate
• CAS NO: 22479-95-4
• Molecular Formula: C₁₀H₁₀O₅
• Molecular Weight: 210.18
• EINECS: 245-023-9
• Mol File: 22479-95-4.mol
• Article Data: 29

Chemical Properties

• Melting Point: 110-111℃
• Boiling Point: 330.6±22.0℃ (760 Torr)
• Flash Point: 129.3±15.8℃
• Appearance: white solid
• Density: 1.284±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 8.58E-05mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.54±0.18(Predicted)
• CAS DataBase Reference: DIMETHYL 4-HYDROXYPHTHALATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIMETHYL 4-HYDROXYPHTHALATE(22479-95-4)
• EPA Substance Registry System: DIMETHYL 4-HYDROXYPHTHALATE(22479-95-4)

Safety Data

• Hazardous Substances Data: 22479-95-4(Hazardous Substances Data)

Usage

Chemical Properties

white solid

Synthesis Reference(s)

Tetrahedron Letters, 18, p. 611, 1977 DOI: 10.1016/S0040-4039(01)92706-6

InChI:InChI=1/C10H10O5/c1-14-9(12)7-4-3-6(11)5-8(7)10(13)15-2/h3-5,11H,1-2H3

Upstream product

• 54125-02-9 danishefsky's diene 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 131-11-3 phthalic acid dimethyl ester 
• 610-35-5 4-hydroxyphthalic acid 
• 483-84-1 8-hydroxy-5,7-dinitro-2-naphthalenesulfonic acid 
• 89-08-7 4-sulfophthalic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 59414-23-2 1-methoxy-3-<(trimethylsilyl)oxy>01,3-butadiene 
• 67-56-1 methanol 

Downstream Products

• 332370-51-1 4-(2-nitrophenoxy)phthalic acid dimethyl ester 
• 1001327-32-7 C₁₃H₁₂N₂O₅S 
• 65687-25-4 dimethyl 4-(3-phenoxypropoxy)phthalate 
• 268234-31-7 dimethyl 4-[3-((E)-1,5-diethyltriethylsilanyloxyhept-1-enyl)phenylmethoxy]phthalate 
• 1161867-84-0 C₇₁H₆₄O₂₃ 
• 341006-33-5 Dimethyl 4-[4'-(2-ethyl-[1,3]dioxolan-2-yl)-2'-methylbiphenyl-3-ylmethoxy]phthalate 
• 1603818-42-3 dimethyl (2S,4S)-2-(benzyloxy)-4-(5-methoxy-1,3-dioxoisoindolin-2-yl)-2-phenylcyclopentane-1,1-dicarboxylate 
• 28281-76-7 5-methoxyisobenzofuran-1,3-dione 
• 610-35-5 4-hydroxyphthalic acid 
• 4376-18-5 Monomethyl phthalate 

Relevant articles and documents

Product-oriented chemical surface modification of a levansucrase (SacB): Via an ene-type reaction

Carbohydrate processing enzymes are sophisticated tools of living systems that have evolved to execute specific reactions on sugars. Here we present for the first time the site-selective chemical modification of exposed tyrosine residues in SacB, a levansucrase from Bacillus megaterium (Bm-LS) for enzyme engineering purposes via an ene-type reaction. Bm-LS is unable to sustain the synthesis of high molecular weight (HMW) levan (a fructose polymer) due to protein-oligosaccharide dissociation events occurring at an early stage during polymer elongation. We switched the catalyst from levan-like oligosaccharide synthesis to the efficient production of a HMW fructan polymer through the covalent addition of a flexible chemical side-chain that fluctuates over the central binding cavity of the enzyme preventing premature oligosaccharide disengagement.

Crystal growth, structure, and polymorphic behavior of an ionic liquid: Phthalate derivative of N -Butyl, N -methylimidazolium Hexafluorophosphate

After the multistep synthesis of an original imidazolium hexafluorophosphate ionic liquid, [pbmim][PF6], two polymorphic forms were isolated from methanolic solution and characterized by XRPD, DSC, and Raman spectroscopy. Stable Form A (mp 90.3 °C) was obtained by conventional crystallization at a moderate cooling rate (10 K/min) was applied. Structural analyses carried out by using single-crystal (Form A) and powder (Form B) X-ray diffraction revealed a rotational disorder of anionic octahedrons and, more interestingly, large conformational differences between cationic moieties caused by their molecular flexibility. Crystal growth of [pbmim][PF6] (Form A) in methanol often leads to numerous crystal defects and revealed that most of them consist of liquid inclusions. The supersaturation ratio (β) appeared to be the predominant factor influencing the crystal growth behavior under isothermal and stagnant conditions. At low β values, a morphological transition from rod-shaped crystals to platelets was observed, presumably caused by a change in the growth mechanism of specific faces. Using high β values promotes either the formation of microscopic (5 μm) liquid inclusions that become easily detectable upon heating or the appearance of macroscopic inclusions with an hourglass shape.

Correlations between carbon-13 nuclear magnetic resonance chemical shifts and reactivities of siloxybutadienes and siloxyazabutadienes in the Diels-Alder reaction with dimethyl acetylenedicarboxylate

-

Iron-catalyzed arene C-H hydroxylation

The sustainable, undirected, and selective catalytic hydroxylation of arenes remains an ongoing research challenge because of the relative inertness of aryl carbon-hydrogen bonds, the higher reactivity of the phenolic products leading to over-oxidized by-products, and the frequently insufficient regioselectivity. We report that iron coordinated by a bioinspired L-cystine-derived ligand can catalyze undirected arene carbon-hydrogen hydroxylation with hydrogen peroxide as the terminal oxidant. The reaction is distinguished by its broad substrate scope, excellent selectivity, and good yields, and it showcases compatibility with oxidation-sensitive functional groups, such as alcohols, polyphenols, aldehydes, and even a boronic acid. This method is well suited for the synthesis of polyphenols through multiple carbon-hydrogen hydroxylations, as well as the late-stage functionalization of natural products and drug molecules.

NOVEL BROMINATED FURANONE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel brominated furanone derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient, wherein the novel brominated furanone derivative or a pharmaceutically acceptable 5 salt thereof according to the present invention exhibits a quorum sensing inhibitory activity of bacteria and also can effectively inhibit the formation of biofilm of bacteria, and thus can be used as a pharmaceutical composition containing the same as an active ingredient, thereby having an effect of being useful, 10 for example, for periodontal diseases such as gingivitis and periodontitis, oral diseases, and the like.